Entrada Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Entrada Therapeutics, Inc. - overview
Established
2016
Location
Boston, MA, US
Primary Industry
Biotechnology
About
Based in Boston, US and founded in 2016 by Dehua Pei and Leo Qian, Entrada Therapeutics, Inc. is a biotechnology company that develops treatments for devastating diseases using intracellular biologics. Entrada Therapeutics has raised a total of USD 175. 60 million in funding over 3 rounds.
In March 2021, Entrada Therapeutics, Inc. raised USD 116 million in series B funding led by new investor Wellington Management Company. In October 2021, the company raised USD 181. 5 million in its IPO and got listed on NASDAQ under the ticker symbol TRDA.
Entrada Therapeutics, Inc. develops and sells Endosomal Escape Vehicle (EEVTM) technology, which allows for the efficient intracellular delivery of proteins, peptides, and nucleic acids, allowing for the development of programs for intracellular target classes and the treatment of a variety of neuromuscular diseases. Entrada Therapeutics, Inc. intends to move its platform and pipeline into clinical trials.
Current Investors
5AM Ventures, MPM BioImpact, Roche Venture Fund
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Bioinformatics
Website
www.entradatx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.